Dakarbazyn | Dacarbazine-RENEVEN for injection lyophil. 100 mg vials 1 pc.
Special Price
$17.46
Regular Price
$26.00
In stock
SKU
BID496443
Latin name
DACARBAZIN-LANS
DACARBAZIN-LANS
Latin name
DACARBAZIN-LANS
Release form
Lyophilisate for solution for iv administration.
Packing
Bottle 0.1 g of lyophilisate. In the package 1 bottle.
Pharmacological action
Pharmacodynamics
Antitumor agent alkylating action. Interacts with SH groups. It inhibits the synthesis of purine bases and DNA.
Pharmacokinetics
Low protein binding. Penetrates through the BBB in limited quantities. Intensively metabolized in the liver. T1 / 2 in the initial phase is 19 minutes, in the final - 5 hours. With impaired renal and hepatic function, T1 / 2 increases. It is excreted by the kidneys unchanged and in the form of metabolites - 40% for 6 hours.
Indications
Malignant melanoma
lymphogranulomatosis
soft tissue sarcoma.
It is possible to use it as a second-line drug in:
testicular tumors
malignant neoplasms of the gastrointestinal tract and neuroblastoma.
Contraindications
Myelodepression
pregnancy
hypersensitivity to dacarbazine.
Use during pregnancy and lactation
Dacarbazine is contraindicated in pregnancy. If necessary, use during lactation, breastfeeding should be discontinued.
Women of childbearing age should use reliable methods of contraception.
Experimental studies have revealed the toxic effects of dacarbazine on the fetus.
Composition
1 vial contains:
Active ingredient: Dacarbazine 100 mg
Excipients: citric acid 100 mg
mannitol 50 mg
Dosage and administration
Set individually, depending on the indications and stage of the disease, the state of the hematopoietic system, anti-tumor therapy regimen.
Side effects
From the hematopoietic system: leukopenia, thrombocytopenia, anemia.
From the digestive system: anorexia, nausea, vomiting, diarrhea, stomatitis in some cases - impaired liver function, hepatic vein thrombosis, toxic liver dystrophy.
From the reproductive system: amenorrhea, azoospermia.
Dermatological reactions: alopecia, skin rash.
Other: hyperemia, facial hypesthesia in isolated cases - impaired renal function.
After a single dose at a high dose: the development of a flu-like syndrome is possible, accompanied by fever and myalgia.
Drug Interaction
Taking 200 mg of ketoconazole once daily increases the plasma concentration of orally administered budesonide at a dose of 3 mg by an average of 6 times. When ketoconazole is administered 12 h after budesonide administration, the concentration of the latter
When used with phenobarbital, azathioprine or 6-mercaptopurine, the toxic effect of dacarbazine is increased.
Storage conditions
Store in a dry, dark place at 2-8 РC.
Shelf life
2 years.
Deystvuyushtee substance
Dacarbazine
Terms and conditions
prescription
Dosage form
infusion solution
Possible product names
Dakarbazin-Lance 100mg lyoph.por. d / in / in. Fl. X1 B (R)
DAKARBAZIN-LENS LIOF. POR. 100 MG FL. No. 1
Dakarbazin-LENS vials 0.1 g, 1 pc.
DACARBAZIN-LANS
Release form
Lyophilisate for solution for iv administration.
Packing
Bottle 0.1 g of lyophilisate. In the package 1 bottle.
Pharmacological action
Pharmacodynamics
Antitumor agent alkylating action. Interacts with SH groups. It inhibits the synthesis of purine bases and DNA.
Pharmacokinetics
Low protein binding. Penetrates through the BBB in limited quantities. Intensively metabolized in the liver. T1 / 2 in the initial phase is 19 minutes, in the final - 5 hours. With impaired renal and hepatic function, T1 / 2 increases. It is excreted by the kidneys unchanged and in the form of metabolites - 40% for 6 hours.
Indications
Malignant melanoma
lymphogranulomatosis
soft tissue sarcoma.
It is possible to use it as a second-line drug in:
testicular tumors
malignant neoplasms of the gastrointestinal tract and neuroblastoma.
Contraindications
Myelodepression
pregnancy
hypersensitivity to dacarbazine.
Use during pregnancy and lactation
Dacarbazine is contraindicated in pregnancy. If necessary, use during lactation, breastfeeding should be discontinued.
Women of childbearing age should use reliable methods of contraception.
Experimental studies have revealed the toxic effects of dacarbazine on the fetus.
Composition
1 vial contains:
Active ingredient: Dacarbazine 100 mg
Excipients: citric acid 100 mg
mannitol 50 mg
Dosage and administration
Set individually, depending on the indications and stage of the disease, the state of the hematopoietic system, anti-tumor therapy regimen.
Side effects
From the hematopoietic system: leukopenia, thrombocytopenia, anemia.
From the digestive system: anorexia, nausea, vomiting, diarrhea, stomatitis in some cases - impaired liver function, hepatic vein thrombosis, toxic liver dystrophy.
From the reproductive system: amenorrhea, azoospermia.
Dermatological reactions: alopecia, skin rash.
Other: hyperemia, facial hypesthesia in isolated cases - impaired renal function.
After a single dose at a high dose: the development of a flu-like syndrome is possible, accompanied by fever and myalgia.
Drug Interaction
Taking 200 mg of ketoconazole once daily increases the plasma concentration of orally administered budesonide at a dose of 3 mg by an average of 6 times. When ketoconazole is administered 12 h after budesonide administration, the concentration of the latter
When used with phenobarbital, azathioprine or 6-mercaptopurine, the toxic effect of dacarbazine is increased.
Storage conditions
Store in a dry, dark place at 2-8 РC.
Shelf life
2 years.
Deystvuyushtee substance
Dacarbazine
Terms and conditions
prescription
Dosage form
infusion solution
Possible product names
Dakarbazin-Lance 100mg lyoph.por. d / in / in. Fl. X1 B (R)
DAKARBAZIN-LENS LIOF. POR. 100 MG FL. No. 1
Dakarbazin-LENS vials 0.1 g, 1 pc.
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review